Status:
COMPLETED
A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma
Lead Sponsor:
Astellas Pharma Inc
Collaborating Sponsors:
Astellas Pharma US, Inc.
Conditions:
Melanoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
A study with YM155 for the treatment of unresectable stage III or metastatic stage IV melanoma.
Detailed Description
A phase II, multicenter, open-label study in subjects with unresectable Stage III or metastatic (Stage IV) Melanoma to evaluate the efficacy and safety of YM155
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed unresectable stage III or IV malignant melanoma
- Life expectancy \>12 weeks
Exclusion
- History of other malignancy in the last 5 years
- Major surgery within the past 21 days
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2007
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT00281541
Start Date
November 1 2005
End Date
June 1 2007
Last Update
June 7 2012
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Tuscon, Arizona, United States, 85724
2
Little Rock, Arkansas, United States, 72205
3
Aurora, Colorado, United States, 80045
4
Washington D.C., District of Columbia, United States, 20010